Scancell Holdings plc, („Scancell‟ or the „Company‟) the developer of novel immunotherapies for the treatment of cancer , announces results for the year ended 30 April 2013.
Highlights during the period:
Post period highlights:
Richard Goodfellow, Joint CEO of Scancell, said:
“We have made excellent progress this year with the successful completion of Part 1 of our Phase 1/2 clinical trial for SCIB1, Part 2 remains on track and our additional 8mg dose study has also commenced. We are delighted that four of the six patients from the 2mg and 4mg dose groups are still alive with one patient remaining disease free two years after initiating treatment.
“We believe our innovative Moditope™ platform has the potential to generate a new class of powerful cancer immunotherapy treatments. We are putting funding in place to identify a lead from this programme and develop it through to the point at which we have secured regulatory approval to start clinical trials, a key value inflexion point. We are confident that such targeted further development of the Immunobody® and Moditope™ platforms will both strengthen Scancell‟s position as a leading immunotherapy player and allow it to realise an enhanced value for shareholders.”
For Further Information:
Scancell Holdings Plc + 44 (0) 74 2323 0 497
Dr Richard Goodfellow, Joint CEO
Professor Lindy Durrant, Joint CEO
Cenkos Securities: +44 (0) 20 7397 8900
FTI Consulting +44 (0) 20 7831 3113
Mon, 19 Aug 2019 11:32:00
Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date
Mon, 19 Aug 2019 06:46:00
The immunotherapy specialist gave an update on progress for a “busy and productive” half-year.
Mon, 01 Jul 2019 11:19:00